

Attorney Docket No. 36290-0415-00-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS THE DESIGNATED/ELECTED OFFICE

In Re Patent Application Of: Patrick Gerard JOHNSTON; Daniel LONGLEY

Application No.:

Not Yet Assigned

(International Application No. PCT/GB2004/005006)

Filing Date:

--

(International Filing Date: 26 November 2004 (26.11.2004))

Customer No.:

23973

Invention:

CANCER TREATMENT

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The present application is a 371 of PCT/GB2004/005006. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate is a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. It is believed that copies of the references have been or will be forwarded by the International Search Authority. Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label No:

EV 545927615 US

Date of Deposit:

sit: 26 May 2006

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL—POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Signature of person mailing page:

Leola P. Goodman

Type or print name of person

101930748 14820636666660700026

Attorney Docket No. 36290-0415-00-US

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more references do not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

PATRICK GERARD JOHNSTON, et al.

RY

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996

TEL: (215) 988-3312 FAX: (215) 988-2757

Attorney for Applicants

IAP20 Rec'arciano 26 MAY 2006

SHEET _1_OF _2

| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | 36290-0415-00-US FILING DATE | PCT/GB2004/005006 PCT/GB2004/005006 PCS. SERIAL NO. Not Yet Assigned |
|--|------------------------------------|--|
| INFORMATION DISCLOSURE CITATION | APPLICANT(S): Patrick Gerard JOHNS | STON, et al. |
| | INTERNATIONAL FILING DATE: | GROUP ART UNIT: |
| | November 26, 2004 | Not Yet Assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IFAPPROPRIATE) |
|---------------------|---|-----------------|------|------|-------|----------|--------------------------------|
| | - | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | 10. | | | | | | |
|--|----|-----------------|------------|---------|-------|----------|----------------|-------|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLA YES | NO NO |
| | AA | WO 03/035868 A | 05/01/2003 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | HYER, M.L. et al., "Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated |
|----------|----|---|
| | AB | apoptosis" CANCER BIOLOGY & THERAPY, Vol. 1:4 (July 2002) pp. 401-406 |
| | AC | USLU, R. et al., "Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis" CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US. Vol. 3:6 (June 1997) pp. 963-972 |
| - | AD | THEARD, D. et al., "Etoposide and Adriamycin but not Genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR" <i>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</i> , Vol. 289 (2001) pp. 1199-1204 |
| | AE | GUROVA, K.V. et al., "Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells" CANCER RESEARCH, Vol. 63 (June 1 2003) pp. 2905-2912 |
| | AF | IWASE, M. et al., "Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by Cisplatin and 5-Fluorouracil" <i>INTERNATIONAL JOURNAL OF CANCER</i> , Vol. 106 (Sep 10 2003) pp. 619-625 |
| | AG | WAKASA, T. et al, "The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumor suppressing effect in human oral squamous cell carcinoma" THE BRITISH JOURNAL OF RADIOLOGY, Vol. 75 (2002) pp. 657-662 |
| | АН | SIEGMUND, D. et al., "Selective inhibition of FLICE-like Inhibitory Protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis" MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, Vol. 8:11 (Nov 2002) pp. 725-732 |
| EXAMINER | | DATE CONSIDERED |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

SHEET 2 OF 2

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 36290-0415-00-US INTERNATIONAL SERIAL NO.
PCT/GB2004/005006

401

CONTRACTOR

FILING DATE

Not Yet Assigned

INFORMATION DISCLOSURE CITATION

APPLICANT(S):

Patrick Gerard JOHNSTON, et al.

INTERNATIONAL FILING DATE:

GROUP ART UNIT:

November 26, 2004

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| AI | DATABASE EMBL-EBI "Homo sapiens FLICE-like inhibitory protein long form mRNA, complete cds." Database accession no. U97074 (July 1, 1999) |
|----------|--|
| AJ | KAMARAJAN, P. et al., "Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signaling" <i>BIOCHEMICAL JOURNAL</i> , Vol. 376:1 (Nov 15 2003) pp. 253-260 |
| AK | MAY, E. et al., "Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene" ONCOGENE, Vol. 6:8 (1991) pp. 1363-1366 |
| AL | PEDERSEN, I.M. et al., "The triterpenoid CDDO induces apoptosis in refractory CLL B cells" <i>BLOOD</i> , Vol. 100:8 (Oct 15 2002) pp. 2965-2972 |
| AM | inhibited by FLICE inhibitor protein and bc1-2" CANCER RESEARCH, vol. 61 (Julie 13 2001) pp. 4804-4872 |
| AN | MICHEAU, O., "Cellular FLICE-inhibitory protein: an attractive therapeutic target?" EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, Vol. 7:4 (Aug 2003) pp. 559-573 |
| | |
| EXAMINER | DATE CONSIDERED |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

IAP20Rossifición 26 may 2006

SHEET 1 OF 2

| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | 36290-0415- | 00-TIS | PCT/G | B2004/0050 | | |
|--|---------------------------------|---|--|---|---|--|--|---|---------------------|--|
| | | | | | FILING DATE | | | Not Yet Assigned | | |
| INI | INFORMATION DISCLOSURE CITATION | | | | | APPLICANT(S): Patrick Gerard JOHNSTON, et al. | | | | |
| | | | | November 2 | | Not Ye | et Assigned | | | |
| | | | U.S. PATEN | NT DOC | UMENTS | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | | CLASS | SUBCLASS | FILING DATE (IFAPPROPRIAT) | E) | |
| | <u></u> | | | <u> </u> | | | | 1 | | |
| | Ī | DOCUMENT NUMBER | DATE DATE | COUNTRY | OCUMENTS | CLASS | SUBCLASS | TRANSLATIC YES 1 | NO NO | |
| | AA | WO 03/035868 A | 05/01/2003 | wo | | | | 123 | <u></u> | |
| | | THED DOCUMEN | NTS (Including | 4 .7 | | | | | | |
| | U | THER DOCUMEN | N I S (Including | z Autnor, | . Title, Date, Pe | ertinent Pa | ges, Etc.) | | | |
| | АВ | HYER, M.L. et al., "I apoptosis" CANCER | Downregulation o | f c-FLIP s ERAPY, V | ensitizes DU145 p ol. 1:4 (July 2002) | pp. 401-406 | er cells to Fas | | | |
| | 1 | HYER, M.L. et al., "I apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US. Vol. | Downregulation of BIOLOGY & THE mosensitization of CAL CANCER R. 3:6 (June 1997) | f c-FLIP s ERAPY, Vo of human p ESEARCH pp. 963-9' | ensitizes DU145 pol. 1:4 (July 2002) prostate carcinoma I, THE AMERICA 72 | pp. 401-406 cell lines to V ASSOCIAT | er cells to Fas anti-Fas-med TION FOR CA | iated cytotoxici | ity | |
| | AB | HYER, M.L. et al., "I apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US, Vol. THEARD, D. et al., "independently of ATM 289 (2001) pp. 1199-1 | Downregulation of BIOLOGY & THE IMPORT THE IMPORT OF THE I | f c-FLIP s ERAPY, Ve of human p ESEARCH pp. 963-9' driamycin EMICAL A | ensitizes DU145 pol. 1:4 (July 2002) rostate carcinoma I, THE AMERICA TO | pp. 401-406 cell lines to N ASSOCIAT can activate t L RESEARC | er cells to Fas anti-Fas-med TION FOR CA he checkpoin TH COMMUN | iated cytotoxicianCER t kinase Chk2 | | |
| | AB AC | HYER, M.L. et al., "I apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US, Vol. THEARD, D. et al., "independently of ATM 289 (2001) pp. 1199-1 GUROVA, K.V. et al carcinoma cells" CAM | Downregulation of BIOLOGY & THE PROPERTY OF TH | f c-FLIP s ERAPY, Vo of human p ESEARCH pp. 963-9' Iriamycin EMICAL A f two muta H, Vol. 63 | ensitizes DU145 pol. 1:4 (July 2002) prostate carcinoma <i>I, THE AMERICA</i> 72 but not Genistein <i>ND BIOPHYSICA</i> ant p53 alleles con (June 1 2003) pp | pp. 401-406 cell lines to NASSOCIAT can activate t L RESEARC tributes to Fa 2905-2912 | anti-Fas-med FION FOR CATHER COMMUNITY COMMUNITY TO STATE THE COMMUNITY OF | iated cytotoxicianCER t kinase Chk2 IICATIONS, Vo | ol. | |
| | AB AC AD | HYER, M.L. et al., "I apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US, Vol. THEARD, D. et al., "independently of ATM 289 (2001) pp. 1199-1 GUROVA, K.V. et al carcinoma cells" CAM IWASE, M. et al., "En by Cisplatin and 5-Flue 625 | Downregulation of BIOLOGY & THE PROSENSITION OF CAL CANCER R. 3:6 (June 1997) Etoposide and AcM/ATR" BIOCHE 1204 ., "Cooperation of CER RESEARCH THANCE SUSCEPTION OF CERTAIN OF CE | f c-FLIP s ERAPY, Vo of human p ESEARCH pp. 963-9' driamycin EMICAL A f two muta H, Vol. 63 bility of or RNATION | ensitizes DU145 pol. 1:4 (July 2002) prostate carcinoma J. THE AMERICA J. 72 but not Genistein ND BIOPHYSICA ant p53 alleles con (June 1 2003) pp al squamous cell call JOURNAL OF | pp. 401-406 cell lines to VASSOCIAT can activate t L RESEARC tributes to Fa 2905-2912 carcinoma cel | anti-Fas-med FION FOR CATTON FOR | iated cytotoxicianCER It kinase Chk2 IICATIONS, Votof prostate -mediated apop 10 2003) pp. 6 | ol. | |
| | AB AC AD AE | HYER, M.L. et al., "I apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US, Vol. THEARD, D. et al., "independently of ATM 289 (2001) pp. 1199-1 GUROVA, K.V. et al carcinoma cells" CAM IWASE, M. et al., "En by Cisplatin and 5-Flu 625 WAKASA, T. et al, "recombinant adenovir THE BRITISH JOUR. | Downregulation of BIOLOGY & THE emosensitization of CAL CANCER R. 3:6 (June 1997) Etoposide and AcM/ATR" BIOCHE 1204 "Cooperation of CER RESEARCE Inhanced susceptibution of the combination rus induced a proposition of the combination of the | f c-FLIP s ERAPY, Vo of human p ESEARCH pp. 963-9' driamycin EMICAL A f two muta H, Vol. 63 oility of or RNATION of ionizin minent tun LOGY, Vo | ensitizes DU145 pol. 1:4 (July 2002) prostate carcinoma I, THE AMERICA TO | pp. 401-406 cell lines to N ASSOCIAT can activate t L RESEARC tributes to Fa 2905-2912 carcinoma cel CANCER, V pression of a fect in human 57-662 | anti-Fas-med TION FOR CATHE CHECKPOINT AS resistance of the checkpoint of the checkp | iated cytotoxicianCER It kinase Chk2 IICATIONS, Votof prostate -mediated apop 10 2003) pp. 6 3 gene via ous cell carcino | ol. | |
| | AB AC AD AE AF | HYER, M.L. et al., "L apoptosis" CANCER I USLU, R. et al., "Che and apoptosis" CLINI RESEARCH, US, Vol. THEARD, D. et al., "independently of ATM 289 (2001) pp. 1199-1 GUROVA, K.V. et al carcinoma cells" CAM IWASE, M. et al., "En by Cisplatin and 5-Flu 625 WAKASA, T. et al, " recombinant adenovir | Downregulation of BIOLOGY & THE Emosensitization of CAL CANCER R. 3:6 (June 1997) Etoposide and Active MATR" BIOCHE 1204 "Cooperation of CER RESEARCE Inhanced susceptible uprouracil" INTEL The combination rus induced a proposition of NAL OF RADIOL I., "Selective inhibitionucleotides (siR) | f c-FLIP s ERAPY, Vo of human p ESEARCH pp. 963-9' driamycin EMICAL A f two muta H, Vol. 63 bility of or RNATION of ionizin minent tun LOGY, Vo bition of F NAs) is su | ensitizes DU145 pol. 1:4 (July 2002) prostate carcinoma I, THE AMERICA TO TO BIOPHYSICA ant p53 alleles con (June 1 2003) pp al squamous cell of AL JOURNAL OF gradiation and expor suppressing ef I. 75 (2002) pp. 6 LICE-like Inhibito fficient to sensitiz | pp. 401-406 cell lines to N ASSOCIAT can activate t L RESEARC tributes to Fa 2905-2912 carcinoma cel CCANCER, V pression of a fect in human 57-662 ory Protein (Fe tumor cells | anti-Fas-med TION FOR CATION FOR | iated cytotoxicianCER It kinase Chk2 IICATIONS, Votof prostate -mediated apop 10 2003) pp. 6 3 gene via ous cell carcinomion with small induced apoptos | otosi 19- ma' | |

IAPZONGO LI GOOD BLO 23 MAY 2006.

10/580748 sHEET 2 OF 2

| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | 36290-0415-00-US FILING DATE | PCT/GB2004/005006 U.S. SERIAL NO. Not Yet Assigned |
|--|--|---|
| INFORMATION DISCLOSURE CITATION | APPLICANT(S): Patrick Gerard JOHN INTERNATIONAL FILING DATE: | STON, et al. GROUP ART UNIT: |
| | November 26, 2004 | Not Yet Assigned |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | О | THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|-----------|-----------------|--|--|--|
| | A 1 | DATABASE EMBL-EBI "Homo sapiens FLICE-like inhibitory protein long form mRNA, complete cds." | | |
| | ΑĪ | Database accession no. U97074 (July 1, 1999) | | |
| | AJ | KAMARAJAN, P. et al., "Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to | | |
| | AJ | CD95/Fas death signaling" BIOCHEMICAL JOURNAL, Vol. 376:1 (Nov 15 2003) pp. 253-260 | | |
| | AK | MAY, E. et al., "Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse | | |
| | AK | deletion mutant p53 gene" ONCOGENE, Vol. 6:8 (1991) pp. 1363-1366 | | |
| | AL | PEDERSEN, I.M. et al., "The triterpenoid CDDO induces apoptosis in refractory CLL B cells" BLOOD, Vol. | | |
| | AL | 100:8 (Oct 15 2002) pp. 2965-2972 | | |
| | AM | POULAKI, V. et al., "Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is | | |
| | Alvi | inhibited by FLICE inhibitor protein and bc1-2" CANCER RESEARCH, Vol. 61 (June 15 2001) pp. 4864-4872 | | |
| | AN | MICHEAU, O., "Cellular FLICE-inhibitory protein: an attractive therapeutic target?" EXPERT OPINION ON | | |
| | AIN | THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, Vol. 7:4 (Aug 2003) pp. 559-573 | | |
| | | | | |
| | | | | |
| | | | | |
| EXAMINER | | DATE CONSIDERED | | |
| | | | | |
| | | | | |
| EXAMINER: | Initial if cita | tion considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and | | |
| | | | | |